TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Investigator global assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRO - dermatology life quality index (DLQI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: fasting serum total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of coronary flow reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QLF measurement of the lesion's depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QLF measurement of the lesion's volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QLF measurement of the lesion's Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of the isoform of the protein precursor of beta amyloid platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Benefit Rate at 16 weeks (CBR16) for female subjects with TNBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Benefit Rate at 24 weeks (CBR24) for female subjects with ER+ BC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Benefit Rate at 16 weeks (CBR16) for all male BC subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and adverse event profile
Endpoint domain: Adverse events/effects
Primary endpoint: Progression to severe preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Paediatric basic life support skill level immediately after training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Foreign body airway obstruction management skill level immediately after training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Technical success of the CE Pro System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chinese Version of Verbal Learning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Chinese Version of Selective Reminding Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in Clinical Dementia Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Job Interview Skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ambulatory Systolic & Diastolic Blood Pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ambulatory Systolic & Diastolic Blood Pressure variability change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended phase II dose (RP2D) of nelfinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Emotion Dysregulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Family Conflict
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: incidence of recurrent Clostridium difficile-associated colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Degree of mental fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of weeks of sick leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gestational age at time of termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Serum uric acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary Arterial Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of Pedicle Screw Positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subjective Opioid Withdrawal Total Adjective Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Breakthrough Withdrawal Medication Doses Taken Week 1
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total Number of Breakthrough Withdrawal Medication Doses Taken Week 2
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Parasitological cure at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of occurrence of Grade 3 or higher adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropathy-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of anal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Modified WHO Ordinal Scale (MOS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO Oral Health Questionnaire for Adults or Children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antimicrobial survey
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Child Dental Anxiety Scale (MCDAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients achieving DAS remission response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with at least one symptom questionnaire completed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in PROMIS-G physical subscale score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in PROMIS-G mental subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of subjects who lose at least 5% of their initial weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: culprit-related TVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nonculprit-related TVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Liver functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and biliary outcomes
Primary endpoint: Number of participants who achieve the composite renal endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in the C3 Deposit Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal structural responses to enzyme replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety scales (Simpson-Angus, Barnes Akathisia, AIMS)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Free From Progression (FFP) at 5 Years
Endpoint domain: Mortality/survival
Primary endpoint: Evaluation of children's language development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes Greater Than or Equal to the Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Concentrations Against Protein D (Anti-PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Curve (AUC) of Numerical Rating Scale (NRS) Scores (at Rest) Over 72h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between oral and cervical HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: EDSS-score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in keratometry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody concentration by Elisa
Endpoint domain: Physiological/clinical
Primary endpoint: Baseline rates of sexual HIV transmission risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Who Experience Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Experience Cerebrovascular Accident
Endpoint domain: Mortality/survival
Primary endpoint: AUC variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour response (size)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical efficacy rate (Response, Minor Response, No Response and Indeterminable)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vanderbilt Parent Rating Scales (VPRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Count and motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thresholds of visual perceptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disappear time of ground-glass shadow in the lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anxiety measured by STICSA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in hepatic venous pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AUDIT score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mayo Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incretin effect based on insulin secretory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intradialytic hypotension episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Mitochondrial Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Mitochondrial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vacouver scar scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Factor VIII:C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Thrombin and Antithrombin complexes (TATc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Prothrombin fragments 1+2 (F1+2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Exercise attendance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maximum-tolerated dose (MTD) of NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to crizotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of hysteroscopy
Endpoint domain: Adverse events/effects
Primary endpoint: tolerability failure
Endpoint domain: Adverse events/effects
Primary endpoint: suppression of plasma HIV-1 RNA levels below 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Childhood Behavior Checklist (CBCL) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Low birth weight (LBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression in 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to open with Nassar Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative Complication with Nassar Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability measured by adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Who Survived to Hospital Discharge With Favorable Neurologic Function
Endpoint domain: Mortality/survival
Primary endpoint: Rate of complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale (Overall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale (AM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Liver Histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient and family knowledge, understanding, and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Size and composition of fat globules in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Congruence of Toxoplasma ICT IgG-IgM test and standard predicate test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Related Outcomes
Endpoint domain: Life impact
Primary endpoint: Changes in spontaneous speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ongoing Implantation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in quality of bimanual hand use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in manual dexterity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in heart rhythm disorders diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial blood glucose change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood glucose profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nighttime systolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy on symptoms of Post-Traumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy on symptoms of Burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy on symptoms of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of healing patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of newly tested HIV-positive clients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of clients newly tested HIV-positive who enrolled into HIV/AIDS care within one month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall number newly tested HIV-positive and enrolled into chronic HIV/AIDS-care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Who Achieved ≥ 2 Point Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Smoking Abstinence at 26 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle contractile properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in complicated grief symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: functional wrist range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neopterin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Soluble CD40 Ligand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUCt of Metformin and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Metformin and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Major Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in AUDIT Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical and/or Mycological Efficacy at the End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and/or Mycological Efficacy at the Test-of-Cure Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Satisfaction With the Efficacy of Voriconazole
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With Clinical Benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Oxaliplatin-induced Cold Pain/Unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor localization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients with isolated circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with successful in vivo animal engraftment of isolated circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Cardiopulmonary Exercise Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of Blood Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological stress tolerance: Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Annualized Joint Bleeding Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the mean arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: antifactor X activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in the heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in the cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean area under the concentration-time curve from zero time to 24 hours postdose (AUC(0-24h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-assessed Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate After Treatment With Azacitidine and Entinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbial load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of Participants With Clinical Response at Day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinical Response at Day 365
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Molecular Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cannulation failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Timed 25-Foot Walk (T25W)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Area Under Curve (AUC) 0-24h of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Mean Daily Steps Walked From Baseline to Intervention Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Days Met Daily Step Goal During Intervention Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes